From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs

Core Insights - Eli Lilly is actively developing multiple obesity drugs, including a daily pill and a more powerful injection, building on the success of its weekly shot, Zepbound [1] - The focus in the obesity drug market is shifting from merely weight loss to broader health implications, as indicated by investor reactions to drug trials [2] Company Developments - Eli Lilly's chief scientific officer, Dan Skovronsky, is leading the development of a daily obesity pill and additional injections, with a total of nine obesity drugs currently in clinical trials [1] - The company’s Zepbound has set a benchmark in the obesity drug market, influencing investor expectations for new entrants [2] Industry Trends - The competitive landscape for obesity drugs is intensifying, with companies like Amgen facing challenges in gaining market traction despite promising trial results [2] - Investors are increasingly cautious, as seen with Amgen's MariTide, which showed a 20% weight loss in trials but led to a 5% drop in share price due to concerns over competition with established drugs like Zepbound and Wegovy [2]